# Abeona Therapeutics Q3 2026 Earnings Results

> Abeona Therapeutics reports $13.5M ZEVASKYN revenue growth with 15 patients treated and ABO-801 acquisition for eosinophilic esophagitis.
- Title: Abeona Therapeutics Q3 2026 Earnings Results · The Motley Fool
- Summary: Abeona Therapeutics reports $13.5M ZEVASKYN revenue growth with 15 patients treated and ABO-801 acquisition for eosinophilic esophagitis.
- Keywords: abeona therapeutics, zevaskyn, abo-801, eosinophilic esophagitis, q3 2026, earnings call, phase iii, rare disease, clinical trials, revenue growth, The Motley Fool
- Source: The Motley Fool — https://fool.com/earnings/call-transcripts/2026/11/09/abeona-therapeutics-abeo-q3-2026-earnings-call-transcript
- Author: Motley Fool Transcribing
- Published: 2026-11-09T20:54:42+00:00
- Read time: 2 min
- Topics: abeona therapeutics, zevaskyn, abo-801, eosinophilic esophagitis, q3 2026, earnings call, phase iii, rare disease, clinical trials, revenue growth, finance, money
## Q3 2026 Earnings Results
Abeona Therapeutics reported net revenue of $13.5 million, an 18% increase compared with the prior quarter.
## Patient Treatments
Six patients were treated with ZEVASKYN in the third quarter, bringing the total number of patients treated since launch to 15.
## Qualified Treatment Centers
Eight total sites are now activated in the ZEVASKYN network following the addition of Cincinnati Children's and University of Florida Health.
## Operational Milestones
Four centers now have first-hand ZEVASKYN treatment experience after the Children's Hospital of Philadelphia and the University of Texas Medical Branch completed their first treatments.
## Manufacturing Performance
One lot out of 15 total treated since launch was out of specifications for the pan-CK identity assay, preventing revenue recognition for that specific treatment.
## Net Loss
Net loss of $4.8 million or $0.08 per share, compared with a net loss of $20.2 million or $0.35 per share in the second quarter.
## Research and Development Expenses
Research and development expenses decreased to $3.7 million from $5 million in the prior quarter.
## Selling, General and Administrative Expenses
Selling, general and administrative expenses increased to $17.1 million from $15.8 million in the second quarter.
## Cash Position
Cash position stands at $134.9 million as of September 30, 2026.
## Acquisition of ABO-801
Abeona issued $20 million in common stock to Ellodi Pharmaceuticals for the Phase III-ready orphan drug candidate ABO-801.
## Development Milestones
Up to $30 million is payable upon FDA approval of ABO-801, with additional $30 million tied to commercial milestones.
## Royalties
Low to mid-teens tiered royalties are eligible to be paid to Ellodi on net sales of ABO-801.
## PIPE Financing
$30 million in gross proceeds from a private placement was announced to fund pipeline development and ZEVASKYN commercialization.
## Eosinophilic Esophagitis Prevalence
360,000 diagnosed patients in the U.S. represent the target market for the ABO-801 program.
## Peak Revenue Potential
Greater than $750 million in annual sales is estimated for ABO-801 due to growing disease prevalence.
## ABO-801 Development Costs
$50 million to $60 million is the estimated clinical cost to bring the candidate through to FDA approval.
## Key takeaway

Abeona Therapeutics reported $13.5 million in ZEVASKYN revenue for Q3 2026, treating 15 patients with a Phase III-ready drug candidate for eosinophilic esophagitis.